Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC vs VAC/VI in Intermediate-Risk Rhabdomyosarcoma
NCT00354835Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Dec 2006
- Primary completion
- Dec 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rhabdomyosarcoma (RMS), sponsored by Children's Oncology Group. Started Dec 2006; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT00354835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354835.